Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Condition(s) studied
Investigational drug(s) / intervention(s)
Isolation of anti-Pseudomonas antibodies from type B lymphocytes: Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
Study summary
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.
The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
Eligibility
Primary outcome measure(s)
- Isolation of recombinant human monoclonal antibodies against Pseudomonas aeruginosa — 1 day
Detection of binding of recombinant antibodies to Pseudomonas aeruginosa target proteins by ELISA assay.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chu Grenoble Alpes | Grenoble | France | Recruiting |
More University Hospital, Grenoble trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04335383 on ClinicalTrials.gov ↗ ← All trials in France